On October 5, 2018, the U.S. Food and Drug Administration (FDA) approved the administration of the Gardasil 9 vaccine for women and men between the ages of 28-45 years. Previously the vaccine was indicated for individuals up to the age of 27 years. "Gardasil 9 prevents certain cancers and diseases caused by the nine HPV types covered by the vaccine". Human Papilloma Virus (HPV) can cause head and neck cancer in men and women. It is the cause of most oropharyngeal cancers in United States.  These cancers and their treatment may lead to trismus (limited mouth opening) and dysphagia (difficulty swallowing). 

The expansion in vaccination ages follows a study in which 3,2000 women between the ages 27-45 years were followed for approximately 3.5 years and it was found that Gardasil was 88% effective in preventing certain HPV related infections and cancers. The results were inferred to apply to men as well.

For further information, please see the complete FDA News Release at: 

Add Comment